<DOC>
	<DOC>NCT01339104</DOC>
	<brief_summary>Open label Phase I study of Regorafenib to evaluate cardiovascular safety, tolerability and anti-tumor activity in patients with advanced solid tumors</brief_summary>
	<brief_title>Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity</brief_title>
	<detailed_description />
	<criteria>Male or female subjects &gt;/= 18 years Eastern Cooperative Oncology Group (ECOG) performance status 0 1 Adequate bone marrow, liver, and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to dosing: Hemoglobin (Hb) &gt;/= 9.0 g/dL, Absolute neutrophil count (ANC) &gt;/= 1500/mm³, Platelet &gt;/= 100,000/mm³, Total bilirubin &lt;/= 1.5 times upper limit of normal (ULN), Alkaline phosphatase &lt;/= 4 x ULN Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) &lt;/= 2.5 times ULN (&lt;/= 5.0 x ULN for subjects with liver involvement of their cancer), International Normalized Ratio (INR) or Partial Thromboplastin Time (PTT) &lt; 1.5 x ULN, Serum creatinine &lt;/= 1.5 times ULN and glomerular filtration rate (GFR) &gt;/= 30 ml/min/1.73 m² according to the MDRD (Modified Diet in Renal Disease) abbreviated formula, Lipase &lt;/= 1.5 x ULN Left Ventricular Ejection Fraction (LVEF) &gt;/= 50 % as assessed at the Baseline Multigated Acquisition (MUGA) scan QTc (QT corrected) &lt;/= 470 msec at Screening Having advanced, refractory disease Life expectancy of at least 3 months Recovery from any previous drug/procedurerelated toxicity to Common Toxicological Criteria (CTC) Grade 0 or 1 levels (except alopecia), or to baseline preceding the prior treatment. History of cardiac disease: congestive heart failure &gt; New York Heart Association (NYHA) Class II; active coronary artery disease (unstable angina [anginal symptoms at rest] or newonset angina [began within the last 3 months] or myocardial infarction within the past 6 months). Uncontrolled hypertension (failure of diastolic blood pressure to fall below 90 mmHg, despite the use of &gt;/= 3 antihypertensive drugs or systolic blood pressure greater than 150 mmHg) History of or known human immunodeficiency virus (HIV) infection or active hepatitis B or C. Subjects with serious nonhealing wound, ulcer, or bone fracture Subjects with arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within the 6 months before start of study medication Persistent proteinuria of CTC Grade 3 or higher (&gt; 3.5 g/24 hours, measured by urine protein/creatinine ratio on a random urine sample) Symptomatic metastatic brain or meningeal tumors unless the subject is &gt; 6 months from definitive therapy, has no evidence of tumor growth on an imaging study within 2 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry Clinically significant bleeding (CTC AE Grade 3 or higher) within 30 days before start of study medication. Subjects with seizure disorder requiring anticonvulsant medication History of organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Cardiovascular safety</keyword>
</DOC>